Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients

被引:31
作者
Lacchini, Riccardo [2 ]
Jacob-Ferreira, Anna L. B. [2 ]
Luizon, Marcelo R. [1 ]
Coeli, Fernanda B. [3 ]
Izidoro-Toledo, Tatiane C. [1 ]
Gasparini, Sandra [4 ]
Ferreira-Sae, Maria C. [4 ]
Schreiber, Roberto [4 ]
Nadruz, Wilson, Jr. [4 ]
Tanus-Santos, Jose E. [1 ]
机构
[1] Univ Sao Paulo, Dept Pharmacol, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil
[2] Univ Estadual Campinas, Dept Pharmacol, Fac Med Sci, Campinas, SP, Brazil
[3] Univ Estadual Campinas, Genet & Mol Biol Ctr, Campinas, SP, Brazil
[4] Univ Estadual Campinas, Dept Internal Med, Fac Med Sci, Campinas, SP, Brazil
关键词
Left ventricular hypertrophy; MMP-9; polymorphisms; Heart remodeling; haplotypes; MATRIX METALLOPROTEINASES; HEART-FAILURE; HEALTHY-SUBJECTS; POLYMORPHISM; PLASMA; DYSFUNCTION; PRESSURE; ATHEROSCLEROSIS; INHIBITION; PROMOTER;
D O I
10.1016/j.cca.2010.08.008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Matrix metalloproteinases (MMPs) are involved in cardiac remodeling and are encoded by genes showing genetic polymorphisms that have functional implications. We examined whether MMP-9 genetic polymorphisms are associated with hypertension and with left ventricular (LV) remodeling in hypertensive patients. Methods: We studied 173 hypertensive patients and 137 age, race and gender matched healthy controls. Heart echocardiography was performed in all patients and the following MMP-9 genetic polymorphisms were analyzed: C-T-1562 (rs3918242). -90 (CA)(14-24) (rs2234681) and Q279R (rs17576). Haplo.stats analysis was used to assess whether MMP-9 haplotypes are associated with hypertension. Linear regression analysis was performed to assess whether MMP-9 haplotypes affect LV mass index (LVMI) and other echocardiography parameters. Results: MMP-9 90 (CA)14-24 "HH" genotype (H allele defined by number of CA repeats >= 21) was associated with hypertension (P = 0.0085; OR = 2.321, 95% confidence interval = 1.250 to 4.309). While one MMP-9 haplotype ("C. H, Q") protects against LVMI and end-diastolic diameter increases due to remodeling (P = 0.0490 and P = 0.0367), another MMP-9 haplotype apparently has detrimental effects over both parameters in hypertensive patients ("T, H. Q", P = 0.0015 and P = 0.0057. respectively). Conclusion: Genetic polymorphisms in MMP-9 gene may modify the susceptibility of hypertensive patients to LV remodeling. Further studies are necessary to examine whether these polymorphisms affect clinical events in hypertensive patients. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:1940 / 1944
页数:5
相关论文
共 27 条
  • [1] Matrix metalloproteinases/tissue inhibitors of metalloproteinases - Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease
    Ahmed, SH
    Clark, LL
    Pennington, WR
    Webb, CS
    Bonnema, DD
    Leonardi, AH
    McClure, CD
    Spinale, FG
    Zile, MR
    [J]. CIRCULATION, 2006, 113 (17) : 2089 - 2096
  • [2] BINDING OF GELATINASES A AND B TO TYPE-I COLLAGEN AND OTHER MATRIX COMPONENTS
    ALLAN, JA
    DOCHERTY, AJP
    BARKER, PJ
    HUSKISSON, NS
    REYNOLDS, JJ
    MURPHY, G
    [J]. BIOCHEMICAL JOURNAL, 1995, 309 : 299 - 306
  • [3] Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure
    Altieri, P
    Brunelli, C
    Garibaldi, S
    Nicolino, A
    Ubaldi, S
    Spallarossa, P
    Olivotti, L
    Rossettin, P
    Barsotti, A
    Ghigliotti, G
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (08) : 648 - 656
  • [4] Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease
    Blankenberg, S
    Rupprecht, HJ
    Poirier, O
    Bickel, C
    Smieja, M
    Hafner, G
    Meyer, J
    Cambien, F
    Tiret, L
    [J]. CIRCULATION, 2003, 107 (12) : 1579 - 1585
  • [5] Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection
    Campbell, LG
    Ramachandran, S
    Liu, W
    Shipley, JM
    Itohara, S
    Rogers, JG
    Moazami, N
    Senior, RM
    Jaramillo, A
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (03) : 517 - 528
  • [6] Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats
    Castro, Michele A.
    Rizzi, Elen
    Figueiredo-Lopes, Livia
    Fernandes, Karla
    Bendhack, Lusiane A.
    Pitol, Dimitrius Leonardo
    Gerlach, Raquel E.
    Tanus-Santos, Jose E.
    [J]. ATHEROSCLEROSIS, 2008, 198 (02) : 320 - 331
  • [7] Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects
    Demacq, C
    de Souza, AP
    Machado, AA
    Gerlach, RF
    Tanus-Santos, JE
    [J]. CLINICA CHIMICA ACTA, 2006, 365 (1-2) : 183 - 187
  • [8] A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients
    Demacq, C.
    Vasconcellos, V. B.
    Marcaccini, A. M.
    Gerlach, R. F.
    Machado, A. A.
    Tanus-Santos, J. E.
    [J]. PHARMACOGENOMICS JOURNAL, 2009, 9 (04) : 265 - 273
  • [9] Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects
    Demacq, Caroline
    Vasconcellos, Vivian B.
    Marcaccini, Andrea M.
    Gerlach, Raquel F.
    Silva, Wilson A., Jr.
    Tanus-Santos, Jose E.
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2008, 46 (01) : 57 - 63
  • [10] Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease
    Dini, Frank Lloyd
    Buralli, Simona
    Bajraktari, Gani
    Elezi, Shpend
    Duranti, Emiliano
    Metelli, Maria Rita
    Carpi, Angelo
    Taddei, Stefano
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2010, 64 (05) : 339 - 342